Literature DB >> 14504893

[Transcorneal-paracorneal penetration route for topical application of drugs to the eyt. Mycophenolate mofetil as a model substance].

E Bertelmann1, S Knapp, P Rieck, S Keipert, C Hartmann, U Pleyer.   

Abstract

PURPOSE: Topically applied drugs can penetrate transcorneally or paracorneally (transsclerally). There are only few studies to demonstrate the relationship of both penetration routes. The immuno-modulator mycophenolate mofetil (MMF), ester and pro-drug of mycophenolic acid (MPA), is a promising substance for such studies.
MATERIAL AND METHODS: Rabbit eyes were treated with different preparations of MMF as a cyclodextrin complex (MM-CD) and as a suspension (MMF-SP) and MPA as a cyclodextrin complex (MPA-CD). The concentrations of both compounds were measured in the cornea, conjunctiva, aqueous humor, vitreous body and iris-ciliary body.
RESULTS: Only MPA is detectable in the cornea after application of MMF-CD and MMF-SP. In the aqueous humor high concentrations of MPA are detectable after 60 min. In the iris-ciliary body both MMF and MPA can be found.
CONCLUSION: The intraocularly detected mycophenolate mofetil represents the paracorneally penetrated fraction. After topical application of mycophenolate mofetil in suitable preparations high concentrations of the active substance can be achieved intraocularly. These favourable pharmacokinetic characteristics are promising for new therapeutic strategies in immune-mediated diseases of the anterior part of the eye.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504893     DOI: 10.1007/s00347-003-0898-8

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  14 in total

1.  In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443.

Authors:  A C Allison; S J Almquist; C D Muller; E M Eugui
Journal:  Transplant Proc       Date:  1991-04       Impact factor: 1.066

2.  In vitro corneal permeation of unoprostone isopropyl (UI) and its metabolism in the isolated pig eye.

Authors:  M Babiole; F Wilhelm; C Schoch
Journal:  J Ocul Pharmacol Ther       Date:  2001-04       Impact factor: 2.671

3.  Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes.

Authors:  D S Chien; J J Homsy; C Gluchowski; D D Tang-Liu
Journal:  Curr Eye Res       Date:  1990-11       Impact factor: 2.424

4.  Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide.

Authors:  B Siefert; U Pleyer; M Müller; C Hartmann; S Keipert
Journal:  J Ocul Pharmacol Ther       Date:  1999-10       Impact factor: 2.671

5.  Importance of the noncorneal absorption route in topical ophthalmic drug delivery.

Authors:  I Ahmed; T F Patton
Journal:  Invest Ophthalmol Vis Sci       Date:  1985-04       Impact factor: 4.799

6.  Penetration routes of topically applied eye medications.

Authors:  M G Doane; A D Jensen; C H Dohlman
Journal:  Am J Ophthalmol       Date:  1978-03       Impact factor: 5.258

7.  [Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis].

Authors:  M Zierhut; N Stübiger; W Aboalchamat; H Landenberger; A A Bialasiewicz; K Engelmann
Journal:  Ophthalmologe       Date:  2001-07       Impact factor: 1.059

8.  Penetration into the anterior chamber via the conjunctival/scleral pathway.

Authors:  R D Schoenwald; G S Deshpande; D G Rethwisch; C F Barfknecht
Journal:  J Ocul Pharmacol Ther       Date:  1997-02       Impact factor: 2.671

9.  Relationship between steroid permeability across excised rabbit cornea and octanol-water partition coefficients.

Authors:  R D Schoenwald; R L Ward
Journal:  J Pharm Sci       Date:  1978-06       Impact factor: 3.534

10.  Ocular esterase composition in albino and pigmented rabbits: possible implications in ocular prodrug design and evaluation.

Authors:  V H Lee; S C Chang; C M Oshiro; R E Smith
Journal:  Curr Eye Res       Date:  1985-11       Impact factor: 2.424

View more
  7 in total

Review 1.  [Immunomodulation in penetrating keratoplasty. Current status and perspectives].

Authors:  U Pleyer
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

2.  [Current practice of immune prophylaxis and therapy in perforating keratoplasty. A survey of members of the Cornea Section of the German Ophthalmological Society].

Authors:  E Bertelmann; T Reinhard; U Pleyer
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

3.  [Classification of biomedical research reports as a reference for evidence-based medicine in ophthalmology. A survey considering as example the journal Der Ophthalmologe].

Authors:  H P N Scholl; M Fleckenstein; T U Krohne; F G Holz
Journal:  Ophthalmologe       Date:  2005-12       Impact factor: 1.059

Review 4.  [Immunosuppressives to prevent rejection reactions after allogeneic corneal transplantation].

Authors:  T Lapp; P Maier; F Birnbaum; G Schlunck; T Reinhard
Journal:  Ophthalmologe       Date:  2014-03       Impact factor: 1.059

5.  [Esterase activity of human organotypic cornea construct (HCC) as in vitro model for permeation studies].

Authors:  L Meyer; J Bednarz; C C Müller-Goymann; S Reichl
Journal:  Ophthalmologe       Date:  2005-10       Impact factor: 1.059

Review 6.  [Topical immunosuppressives after penetrating keratoplasty].

Authors:  F Birnbaum; A Reis; T Reinhard
Journal:  Ophthalmologe       Date:  2007-05       Impact factor: 1.059

7.  Potential Link between the Sphingosine-1-Phosphate (S1P) System and Defective Alveolar Macrophage Phagocytic Function in Chronic Obstructive Pulmonary Disease (COPD).

Authors:  Jameel Barnawi; Hai Tran; Hubertus Jersmann; Stuart Pitson; Eugene Roscioli; Greg Hodge; Robyn Meech; Rainer Haberberger; Sandra Hodge
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.